Woei-A-Jin FJSH, Zheng SZ, Kiliçsoy I, et al. - Via a total of 775 adult patients with solid cancer, researchers determined lifetime transfusion burden and transfusion-related iron overload in adult survivors of solid malignancies. Symptomatic anemia or hemoglobin < 8.1–8.9 g/dL were transfusion triggers former to each myelosuppressive chemotherapy cycle. Amongst all tumor types, 123 patients with a lifetime transfusion burden of ≥ 10 RBC units were recognized. In the absence of a hemovigilance program, none of these multi transfused patients were screened for iron overload irrespective of median survival of 4.6 years. Twenty-six multi transfused patients were alive in 2015 at the disclosure of transfusion burden. Six had hepatic iron overload of 3.9–11.2 mg Fe/g dry weight. Cardiac iron depositions were not observed. Thus, even when sticking to restrictive RBC transfusion policies, patients with solid malignancies are at risk for multi transfusion and iron overload. With improved long-term cancer survivorship, a heightened awareness of iatrogenic side impacts of supportive therapy and the development of evidence-based guidelines is required.